Phase II Study of Eloxatin+5-FU/LV in Patients With Unresectable Hepatocellular Carcinoma
Status:
Completed
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
Primary objective:
To determine the Tumor Response Rate of patients with hepatocellular carcinoma treated with
the combination chemotherapy of Eloxatin+5-FU/LV
Secondary objective:
To evaluate time to progression, 6month survival, overall survival, safety and tolerability
of patients with hepatocellular carcinoma treated with the combination chemotherapy of
Eloxatin+5-FU/LV